Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Elevai Labs Releases Preliminary Positive Research on the Potential of Exosome Technology for Skin Health

December 2, 2024 By Cade Hildreth, Founder & President Leave a Comment

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”).

Data implies ELEVAI exosomes™ may be a source for proteins that typically decrease with age, and can be important components that prevent skin thinning, loss of elasticity and wrinkle formation.

[Read more…]

Proudly Supporting Great Science and Women in STEM

December 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

WORD+ 2025 is pleased to introduce its conference chairs and speakers.

FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female. [Read more…]

Taking EV characterization to the next level with ONI’s Nanoimager

November 28, 2024 By Cade Hildreth, Founder & President Leave a Comment

Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.

What is an extra-cellular vesicle?

EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]

Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions

November 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

November 21, 2024, MONT-SAINT-GUIBERT, Belgium — Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs). This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. [Read more…]

Autolus Latest Competitor in Global CAR-T Frenzy with FDA Approval of Aucatzyl

November 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

On November 8, 2024, the U.S. FDA issued a historic approval of the seventh CAR-T cell therapy to be approved in the U.S. and the 11th CAR-T therapy to be approved globally. This approval was for Autolus Inc.’s Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Autolus is a U.K. biotech company that develops novel gene-modified T cell therapies for the treatment of cancer. [Read more…]